An interventional study of sarcopenia and mobility measurement in Sarcopenia and Bladder Cancer, sponsored by University Hospital, Caen. Recruiting at 3 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.
Sponsored by University Hospital, Caen · Not applicable, Interventional, and Diagnostic
Among 78 studies in Sarcopenia with a site in France — 23 open to participants now, 24 under way, none of them phase 3. Sarcopenia · France.
Among the 78 studies in Sarcopenia with a site in France, this one is the 32nd largest by planned enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2017, is one of 49 with no phase, reaches primary completion later than 2 of the 23 other live ones, and was the 18th registered.
1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.
Browse Sarcopenia studies →23 of the 78 studies in Sarcopenia with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 75+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 65+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 75+
Hospices Civils de Lyon · Sites in France
Ages 18–74
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 33 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2017.
This study's planned enrollment of 69 is above the median of 60 across 855 interventional studies indexed under Sarcopenia.
Median enrollment 98 across the 53 interventional studies, 72 across the 25 observational. Of the 38 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 78 have an industry lead sponsor. The 10 most frequent:
University Hospital, Caen is the lead sponsor of 512 studies on the registry; 82 are open to participants now.
University Hospital, Caen has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
9 of the studies in Sarcopenia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04987814Assistance Publique - Hôpitaux de ParisHigh-definition Surface Electromyography Markers for the Diagnosis of Sarcopenia | 2026-11-18 |
| NCT05228262University Hospital, Clermont-FerrandVascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis | 2027-02-01 |
| NCT05488093University Hospital, MontpellierEvaluation of Mobility in Subjects With Severe Knee Osteoarthritis Who Are to Undergo Total Knee Replacement | 2027-03 |
| NCT06963359Assistance Publique - Hôpitaux de ParisHigh-definition Surface Electromyography Markers for the Diagnosis and Monitoring of Sarcopenia | 2027-03 |
| NCT05869487Centre Hospitalier Régional d'OrléansCalf Circumference Versus X-ray Absorptiometry in the Diagnosis of Sarcopenia in Elderly Hospitalized Patients | 2027-04-11 |
Among the 78 studies in Sarcopenia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is associated with lower prognosis in solid tumors, but this has not been studied in bladder carcinoma requiring cystectomy.
According to EWGSOP recommendations, the diagnosis of sarcopenia is based on walking speed, grip strength and muscle mass. These three elements can easily be measured (specially muscle mass measurement by bioimpedencemetry or tomodensitometry).
This cohort study will collect clinical complementary elements to better understand the associated factors present with sarcopenia, in order to prepare an interventional preoperative physical reconditioning study.
The mobility measurement will be carried out by the QAPPA questionnaire (validated in French in the elderly) and the quantitative measurement of activity and rest hours during a week by a wrist actimeter.
Standardized geriatric data will also be collected: ADL, IADL for autonomy, MMSE for cognitive status, nutritional status (% weight loss, BMI), pain, GDS15 for depression screening, updated Charlson Comorbidity Index to identify polypathology and The STOPP tool for potentially inappropriate medication.
Post-operative morbidity mortality at 30 days will be evaluated according to Clavien-Dindo classification. Investigators will also evaluate 6 months geriatric complications : falls, loss of autonomy and decreased mobility and physical activity, cognitive degradation, undernutrition, institutionalization
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed urothelial bladder carcinoma ( RTUV)
Exclusion Criteria:
\<6 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sarcopenic status the day before cystectomy.
Diagnostic Test: sarcopenia and mobility measurement
sarcopenic status the day before cystectomy.
Diagnostic Test: sarcopenia and mobility measurement
walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter. Comprehensive Geriatric Assessment
post-operative morbidity
evaluated according to Clavien-Dindo classification
Time frame: at 30 days
post-operative mortality
Time frame: at 30 days
post-operative complications
Impact of dependancy (PS / ADL / IADL)
Time frame: 8 months
post-operative complications
physical activity scores (QAPPA) Questionnaire d'activité physique pour les personnes âgées in French validated in French population - total score is used
Time frame: 8 months
post-operative complications
physical performance (PBP)
Time frame: 8 months
post-operative complications
fatigue (BFI) Brief Fatigue Inventory questionnaire
Time frame: 8 months
post-operative complications
history of fall
Time frame: 8 months
post-operative complications
pain (visual analogic scale for pain 0 to 10)
Time frame: 8 months
post-operative complications
hours of mobility (actimetry)
Time frame: 8 months
post-operative complications
hours of daily rest (actimetry) measured during 3 consecutives days
Time frame: 8 months
post-operative complications
Actimetry
Time frame: 8 months
post-operative complications
nutritional status (nutritional grade 2 or 4 according to SFNEP Société Francophone Nutrition Clinique et Métabolisme )
Time frame: 8 months
post-operative complications
cognitive status (normal or not)
Time frame: 8 months
post-operative complications
polymedication (≥5 / day)
Time frame: 8 months
post-operative complications
comorbidities (updated charlson)
Time frame: 8 months
post-operative complications
inappropriate prescriptions (STOPP)
Time frame: 8 months
impedancemetric value
Concordance of values (attribution of sarcopenic / non-sarcopenic groups) with impedancemetric value
Time frame: 2 months
sarcopenic status
evolution of sarcopenic status
Time frame: between baseline; preoperative and at 6 months post-operative
quality of life scores
EORTC QLQ-ELD14 (assessment of health-related quality of life elderly patients with cancer with 14 items)
Time frame: preoperative and 6-month post-operative
Not enrolling at this site.
Plan to share: No
Started Oct 2017 (actual). Primary completion is estimated for Jul 2025, 92 months after the start.
Of 492 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 92 months is above that.
Counting every sponsor, half of 503 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.